Sign in

NCT05351424Recruiting

AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc

Audiovisual Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment (ADELANTE) Study in Radiation Oncology

Source: ClinicalTrials.gov · Last updated 12 Feb 2026

Brief summary (registry, in English)

The study aims to develop educational media interventions to prepare Latinx Spanish-speaking radiation oncology patients for a course of breast or prostate cancer radiation therapy and to foster receptivity and informed decision-making around cancer clinical trial participation.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
194 (estimated)
First submitted
31 Mar 2022
Start date
3 May 2022
Primary completion date
31 Dec 2026
Lead sponsor
Columbia University
NCT number
NCT05351424

What you commit to

  • Study type: Interventional
  • Planned participants: 194
  • From 3 May 2022 to the primary completion date, 31 Dec 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Pilot Phase Inclusion Criteria:
  • Spanish speakers of Latinx background as defined by the U.S. Census Bureau as anyone from Mexican, Puerto Rican, Cuban, Dominican, Central or South American ancestry
  • Currently undergoing treatment for breast or prostate cancer, or recently been treated
    • Pilot Phase Exclusion Criteria:
  • Patient with bilateral deafness and/or blindness
  • Patient with psychosis and/or dementia
    • Main Study Inclusion Criteria:
  • Spanish speakers of Latinx background as defined by the U.S. Census Bureau as anyone from Mexican, Puerto Rican, Cuban, Dominican, Central or South American ancestry
  • Patients with non-metastatic prostate or breast cancer
  • Histopathologically proven diagnosis of prostate or breast cancer
  • History and physical examination within 28 days prior to enrollment
  • Karnofsky performance status 70 or greater
  • For women of childbearing potential, pregnancy testing to be performed in accordance to institutional guidelines
  • Plan to receive definitive, curative radiation. Patients planning to receive curative RT after upcoming adjuvant chemotherapy or induction hormonal therapy may enroll at reconsult "follow-up" visit.
  • Consultation visit must be performed with a certified interpreter
    • Main Study Exclusion Criteria:
  • Patient with bilateral deafness and/or blindness
  • Patient with psychosis and/or dementia
  • Clinical or radiological evidence of metastatic disease
  • Prior participation in cancer patient education trial
  • Prior RT
  • RT for sites other than breast or prostate

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Mount Sinai Medical Center
Coordinator of this site? Confirm its status
Miami BeachUnited StatesRecruiting
Columbia University Irving Medical Center
Coordinator of this site? Confirm its status
New YorkUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.